Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Endometrial responses to SERMS investigated
March 31st, 2005
According to a study in the journal Toxicology, "Tamoxifen has long been the endocrine treatment of choice for women with breast cancer and is now employed for prophylactic use in women at high risk from breast cancer." "Other selective estrogen receptor modulators (SERMs), such raloxifene, mimic some of tamoxifen's beneficial effects, and like tamoxifen exhibit a complex mixture of organ-specific estrogen agonist and antagonistic properties. However, accompanying the positive effects of tamoxifen has been the emergence of evidence for an increased risk of endometrial cancer associated with its use. A more complete understanding of the mechanism(s) of SERM...
Source: Women's Health Weekly (2005-03-31)
|
